April 1, 2022
- Built-in walletfor atrial fibrillation offers solutions through electrophysiology, cardiac implantable electronic device (EDIC)lead extraction and ECG monitoring
- New release of Philips KODEX-EPD cardiac imaging and mapping system incorporates new innovations for RF and cryoballoon therapy for cardiac arrhythmias
- Philips reinforces its commitment to facilitate compliance with international best practice guidelines for lead management and extraction
- Wearable ePatch Holter monitor helps diagnose and monitor patients with atrial fibrillation to reduce stroke risk
Amsterdam, Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global health technology leader, showcases its integrated portfolio of atrial fibrillation diagnosis, referral and treatment solutions at the 2022 European Heart Rhythm Annual Meeting Association (EHRA 2022, April 3-5, Copenhagen, Denmark). The launch of the latest version of Philips’ KODEX-EPD system will be one of the highlights of the company’s stand which will support the treatment of the growing number of patients with atrial fibrillation. It offers enhanced imaging and mapping capabilities for RF ablation, including the new Tissue Engagement Viewer and support for the Medtronic DiamondTempMT ablation system. For cryoballoon ablation, KODEX-EPD supports a new saline-based occlusion assessment workflow .
Other highlights include enhancements to the company’s electrophysiology suite; the company’s latest lead management tools for the safe removal of infected leads from implantable cardiac electronic devices; and Philips’ Discreet portable ePatch extended wear Holter monitoring service, part of Philips Ambulatory Monitoring and Diagnostics portfolio. Providing support for confident diagnosis, improved electrophysiology (EP) procedure effectiveness and efficiency, reduced x-ray exposure, and post-procedure therapy monitoring, these new innovations dramatically improve the physician experience. towards optimal treatment of patients with atrial fibrillation (AF).
Atrial fibrillation is the most common cardiac arrhythmia in the world, with a particularly high prevalence in developed countries, partly due to lifestyle and aging populations. The disease, which also greatly increases the risk of stroke, dementia and heart failure, already affects around 37 million people worldwide (about 0.5% of the world’s population) – a number that is expected to double in the next 40 years.
Philips’ Electrophysiology and cardiac lead extraction solutions uniquely leverage imaging systems and software with specialized diagnostic and therapeutic devices designed to support the treatment of the growing number of patients with cardiac arrhythmias. Running on the company’s Azurion platform, Philips Electrophysiology Suite seamlessly integrates imaging, devices, software, computing and services. It assists with every step of a patient’s journey with atrial fibrillation, providing cardiologists with greater understanding and confidence in electrophysiology procedures while enabling them to meet growing clinical demand at an affordable cost.
New KODEX-EPD version with extended compatibility
The latest version of KODEX-EPD, launched at EHRA, showcases a range of innovations for RF and cryoballoon ablation therapy. Enhanced imaging and mapping capabilities assist physicians with precise RF ablation procedures, including the new Tissue Engagement Viewer that provides catheter-tissue contact information without the need for special catheters.
Philips has extended the compatibility of the KODEX-EPD system to support the Medtronic DiamondTempMT ablation system for real-time, temperature-controlled ablation. For cryoballoon ablation, the KODEX-EPD System has a new saline-based occlusion assessment workflow further reducing the need for X-ray imaging with iodinated contrast material, which is especially useful for patients with iodine allergies or chronic kidney disease.
Philips continues to engage with Medtronic to support physicians in ablation procedures to optimize patient outcomes and minimize exposure to x-rays and iodinated contrast media. The results of these activities will be presented at the EHRA Congress in various scientific sessions and at a symposium sponsored by Philips.
Extraction and management of CIED leads
Implantable cardiac electronic devices (CIEDs) such as pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices are lifesaving devices that improve the quality of life for many patients. However, 1 in 20 of these patients develop CIED infection.  within three years. Patients diagnosed with CIED infections are often treated with antibiotics, which is not an effective treatment option on its own. 50% to 100% of patients treated with antibiotics alone will experience a relapse of infection [4,5].
A large EHRA survey conducted in 2020 demonstrated that healthcare professionals lack knowledge and experience in managing CIED infections . According to the latest European Heart Rhythm Association (EHRA) International consensus document , definitive CIED infections are a Class I indication for complete device extraction. Nevertheless, it is estimated that more than 75% of indicated patients do not receive care that meets Class I guidelines, which is a complete extraction of the system, leading to negative health outcomes and higher costs. Philips is committed to supporting evidence-based medical approaches and innovative solutions to help physicians improve outcomes and reduce mortality from CIED infection.
Although adverse events during a procedure can potentially be life-threatening, catheter extraction is a highly effective, potentially life-saving procedure with a 97.7% clinical success rate and safety rate 99.72% procedural. . Philips supports physicians with lead management solutions through a broad portfolio of tools designed for security and predictabilityincluding laser and mechanical lead extraction devices.
When diagnosing AF – a heart irregularity that can lead to blood clots and increase the risk of stroke – it’s important to record its frequency, duration and severity. It is also important to check that the irregularities do not recur in the days and weeks following the treatment. While conventional Holter monitors that perform these assessments have been around for a long time, they typically involve attaching up to seven ECG electrodes to the patient’s chest, linked to a control unit worn on a belt. These can be cumbersome for patients to carry – which can impact diagnostic throughput – while the request process, data analysis and reporting can be laborious and inefficient for clinical staff. Philips ePatch replaces this cumbersome setup with a small, unobtrusive sensor and patches adhered to the patient’s sternum for up to 14 days of continuous, high-quality ECG recording for reliable diagnosis. Philips ePatch is splash proof, can be worn in the shower and allows the patient to maintain an active lifestyle. Philips also provides an end-to-end service for ePatch deployment, supporting efficient workflows, improving patient experience and enabling robust data analysis using our Cardiologs software based on the AI and cloud-based.
For more information and to register for the Philips Lead Management science session with an expert infectious disease and cardiologist or our session on the evolution of next-generation dielectric imaging and ECG monitoring, go to Philips’ EHRA 2022 Webpages.
 GBD 2017 Collaborators on Incidence and Prevalence of Diseases and Injuries, Incidence, prevalence and years lived with disability globally, regionally and nationally for 354 diseases and injuries in 195 countries and territories, 1990-2017: a Systematic review for the Global Burden of Disease Study 2017. Lancet. 2018; 392: 1789-1858.
 Cantillon D, et al. Health care complications and costs associated with transvenous pacemakers in a national assessment. J Am Coll Cardiol EP. 2017 November, 3 (11) 1296–1305.
 del Rio A, Anguera I, Miro JM, et al. Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome. Chest 2003;124:1451–9.
 Chua, JD, et al. (2000). Diagnosis and management of infections involving implantable electrophysiology.
 Archana Rao et al 2020 Knowledge gaps, lack of trust and systemic barriers to guideline implementation among European physicians caring for patients with CIED- or infection-related complications: a survey to assess the educational needs of the European Heart Rhythm Association/European Society of Cardiology. Europace (2020) 0, 1.
 Blomström-Lundqvist C, Traykov V, Erba PA, et al. EP Europace, volume 22, issue 4, April 2020, pages 515–549, https://doi.org/10.1093/europace/euz246.
 Wazni, O. et. al. Lead Mining in the Contemporary Setting: The LExICon Study: A Retrospective Multicenter Observational Study of Consecutive Laser Lead Mining, J Am Coll Cardiol, 55: 579-586.
DiamondTemp and Arctic Front Advance are registered trademarks of the Medtronic companies.
For more information, please contact:
Philips Global Press Office
Tel: +31 6 10 55 8116
E-mail: [email protected]
Fabienne van der Feer
Philips Image Guided Therapy
Tel: + 31 622 698 001
E-mail: [email protected]
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving the health and well-being of people and driving better outcomes in the across the health continuum – from healthy living and prevention to diagnosis, treatment and home care. Philips relies on cutting-edge technology and in-depth clinical and consumer insights to deliver integrated solutions. Based in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as consumer health and care. residence. Philips generated sales of €17.2 billion in 2021 and employs approximately 78,000 employees with sales and service in over 100 countries. Information about Philips can be found at www.philips.com/newscenter.